+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimilar Monoclonal Antibodies Market Report 2022-2032

  • PDF Icon

    Report

  • 461 Pages
  • July 2022
  • Region: Global
  • Visiongain
  • ID: 5806129
Description Jump to:
The Biosimilar Monoclonal Antibodies Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Demand for Cost-Effective Biosimilars

The utilization of biological agents in the manufacturing of biopharma products increases complexity. As a result, biosimilars are not "exact" replicas of their biological counterparts despite being similar in function and intended use. Cancer, rheumatoid arthritis, diabetes, and anemia are just a few of the conditions that are treated with the help of branded biologics and biosimilars. The cost of biosimilar pharmaceuticals is lower than that of branded drugs because they are exact replicas of their branded counterparts.

The rise in advanced monoclonal antibody production, rising geriatric population, and high prevalence of chronic diseases like cancer, renal failure, rheumatoid, psoriasis, diabetes, and others are all factors contributing to the growth of the global biosimilar monoclonal antibodies market. Additionally, the increasing number of mAbs whose patents are about to expire will probably increase market growth potential in the years to come.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the biosimilar monoclonal antibodies market evolving?
  • What is driving and restraining the biosimilar monoclonal antibodies market?
  • How will each biosimilar monoclonal antibodies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • How will the market shares for each biosimilar monoclonal antibodies submarket develop from 2022 to 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading biosimilar monoclonal antibodies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the biosimilar monoclonal antibodies projects for these leading companies?
  • How will the industry evolve during the period between 2020 and 2032? What are the implications of biosimilar monoclonal antibodies projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialization to further scale the biosimilar monoclonal antibodies market?
  • Where is the biosimilar monoclonal antibodies market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the biosimilar monoclonal antibodies market today, and over the next 10 years:

  • Our 461-page report provides 238 tables and 272 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the biosimilar monoclonal antibodies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising biosimilar monoclonal antibodies prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Market Segment by Type

  • Synthetic Chemicals
  • Biopharmaceuticals

Market Segment by Application

  • Chronic & Autoimmune Diseases
  • Oncology Diseases
  • Other Applications

Market Segment by Compound

  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America

  • U.S.
  • Canada
  • Mexico

Europe

  • Germany
  • Spain
  • United Kingdom
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

LAMEA

  • Brazil
  • Turkey
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Latin America
The report also includes profiles and for some of the leading companies in the Biosimilar Monoclonal Antibodies Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

  • 3SBio Inc.
  • AbbVie Inc. (AbbVie)
  • Amgen Inc.
  • BIOCAD
  • Biocon Limited
  • Boehringer Ingelheim
  • Celltrion Healthcare Co Ltd.
  • Dong-A Socio Holdings
  • Dr. Reddy’s Laboratories Ltd
  • Genor Biopharma Holdings Ltd.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Reliance Industries Limited
  • Torrent Pharmaceuticals Limited
Overall world revenue for Biosimilar Monoclonal Antibodies Market, 2022 to 2032 in terms of value the market will surpass US$4,749 million in 2022, this work calculates. We predict strong revenue growth through to 2032. this work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biosimilar Monoclonal Antibodies Market, 2022 to 2032 report help you?

In summary, this 480+ page report provides you with the following knowledge:
  • Revenue forecasts to 2032 for Biosimilar Monoclonal Antibodies Market, 2022 to 2032 Market, with forecasts for type, application, compound and company size, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Biosimilar Monoclonal Antibodies Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Biosimilar Monoclonal Antibodies Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Biosimilar Monoclonal Antibodies Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview
1.1 Introduction to Biosimilar Monoclonal Antibodies Market
1.2 Global Biosimilar Monoclonal Antibodies Market Overview
1.3 What are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Biosimilar Monoclonal Antibodies Market Definition
1.6 Why You Should Read This Report
1.7 What This Report Delivers
1.8 Key Questions Answered By This Analytical Report Include:
1.9 Who is This Report for?
1.10 Research Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Reports
1.13 About the Publisher
2 Executive Summary
2.1 Introduction
3 Biosimilar Monoclonal Antibodies Industry Structure
3.1 Market and Technology Background
3.2 Lifecycle of a Biosimilar Drug
3.3 Development of a Biosimilar
3.4 Cell Line Development and Selection
3.5 E. coli Cells
3.6 Mammalian Cells
3.7 Manufacturing of a Biosimilar
3.8 Preclinical Studies and Validation of a Biosimilar
3.9 Clinical Trials
3.10 Approval by Regulatory Agencies
3.11 Pharmacovigilance/Post-Approval Monitoring
4 Global Market Dynamics
4.1 Market Driving Factors
4.1.1 Biosimilars: Leading the Way to Cost Effective Healthcare
4.1.2 mAbs Will Continue to be a Dominant Therapeutic Modality for Treatment of a Broad Range of Diseases
4.2 Market Restraining Factors
4.2.1 Monoclonal Antibody Complexity and Biosimilar Manufacturing
4.2.2 Several Critical Features of Biosimilar Regulatory Pathway is Yet to be Finalized
4.3 Opportunities in the Global Market
4.3.1 Local Companies Can Help Multinational Biosimilars Companies Improve Sales
4.3.2 Emerging Economies to Offer Lucrative Growth Opportunities
4.4 Challenges in the Global Market
4.4.1 High Cost of Pharmaceuticals Has Become a Key Issue
4.4.2 Unpredictable Regulatory Landscape
4.4.3 Biosimilars Companies Must Address Infrastructure
4.5 PEST Analysis
4.5.1 Political Factors
4.5.2 Economic Factors
4.5.3 Social Factors
4.5.4 Technology Factors
5 Global Biosimilar Monoclonal Antibodies Market Analysis
5.1 Global Market Outlook
5.2 Global Market Size Estimation and Forecast
5.2.1 Pre-COVID-19 Market Scenario
6 Global Biosimilar Monoclonal Antibodies Market by Region
6.1.1 Pre-COVID-19 Market Scenario
6.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Biosimilar Monoclonal Antibodies Market by Type
7.1.1 Synthetic Chemicals
7.1.2 Biopharmaceuticals
7.1.3 Pre-COVID-19 Market Scenario
7.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Biosimilar Monoclonal Antibodies Market by Application
8.1.1 Chronic & Autoimmune Diseases
8.1.2 Oncology
8.1.3 Pre-COVID-19 Market Scenario
8.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Biosimilar Monoclonal Antibodies Market by Compound
9.1.1 Infliximab
9.1.2 Rituximab
9.1.3 Abciximab
9.1.4 Trastuzumab
9.1.5 Adalimumab
9.1.6 Bevacizumab
9.1.7 Pre-COVID-19 Market Scenario
9.1.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 North America Biosimilar Monoclonal Antibodies Market Analysis
10.1 North America Biosimilar Monoclonal Antibodies Market by Value
10.1.1 Pre-COVID-19 Market Scenario
10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.2 North America Biosimilar Monoclonal Antibodies Market by Country
10.2.1 Pre-COVID-19 Market Scenario
10.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.3 U.S. Biosimilar Monoclonal Antibodies Market Analysis
10.3.1 FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes
10.3.2 Pre-COVID-19 Market Scenario
10.3.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.4 Canada Biosimilar Monoclonal Antibodies Market Analysis
10.4.1 Northwest Territories Becomes Fifth Jurisdiction in Canada to Implement Biosimilar Switching Initiative
10.4.2 CGPA / Biosimilars Canada Statement on COVID-19 and the Supply and Distribution of Generic and Biosimilar Prescription Medicines in Canada
10.4.3 Pre-COVID-19 Market Scenario
10.4.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.5 Mexico Biosimilar Monoclonal Antibodies Market Analysis
10.5.1 Mexico: Major Change To The Regulatory Approval System For Biosimilars, Medicines And Medical Devices
10.5.2 Pre-COVID-19 Market Scenario
10.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.6 North America Biosimilar Monoclonal Antibodies Market by Type
10.6.1 Pre-COVID-19 Market Scenario
10.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.7 North America Biosimilar Monoclonal Antibodies Market by Application
10.7.1 Pre-COVID-19 Market Scenario
10.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.8 North America Biosimilar Monoclonal Antibodies Market by Compound
10.8.1 Pre-COVID-19 Market Scenario
10.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Europe Biosimilar Monoclonal Antibodies Market Analysis
11.1 Europe Market Outlook
11.2 Europe Biosimilar Monoclonal Antibodies Market by Value
11.2.1 Pre-COVID-19 Market Scenario
11.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.3 Europe Biosimilar Monoclonal Antibodies Market by Country
11.3.1 Pre-COVID-19 Market Scenario
11.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.4 Germany Biosimilar Monoclonal Antibodies Market Analysis
11.4.1 Pre-COVID-19 Market Scenario
11.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.5 UK Biosimilar Monoclonal Antibodies Market Analysis
11.5.1 Abzena Collaboration
11.5.2 Pre-COVID-19 Market Scenario
11.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.6 France Biosimilar Monoclonal Antibodies Market Analysis
11.6.1 Pre-COVID-19 Market Scenario
11.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.7 Italy Biosimilar Monoclonal Antibodies Market Analysis
11.7.1 Pre-COVID-19 Market Scenario
11.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.8 Spain Biosimilar Monoclonal Antibodies Market Analysis
11.8.1 Bevacizumab Biosimilars Launched in Spain
11.8.2 Pre-COVID-19 Market Scenario
11.8.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.9 Rest of Europe Biosimilar Monoclonal Antibodies Market Analysis
11.9.1 Pre-COVID-19 Market Scenario
11.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.10 Europe Biosimilar Monoclonal Antibodies Market by Type
11.10.1 Pre-COVID-19 Market Scenario
11.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.11 Europe Biosimilar Monoclonal Antibodies Market by Application
11.11.1 Pre-COVID-19 Market Scenario
11.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.12 Europe Biosimilar Monoclonal Antibodies Market by Compound
11.12.1 Pre-COVID-19 Market Scenario
11.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis
12.1 Asia-Pacific Market Outlook
12.2 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value
12.2.1 Pre-COVID-19 Market Scenario
12.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country
12.3.1 Pre-COVID-19 Market Scenarios
12.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.4 China Biosimilar Monoclonal Antibodies Market Analysis
12.4.1 Pre-COVID-19 Market Scenario
12.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.5 India Biosimilar Monoclonal Antibodies Market Analysis
12.5.1 Roche’s Antibody Cocktail (Casirivimab and Imdevimab) Is Now Available In India, Cipla To Market It Pan-India
12.5.2 Pre-COVID-19 Market Scenario
12.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.6 Japan Biosimilar Monoclonal Antibodies Market Analysis
12.6.1 Adalimumab Biosimilar Launched in Japan
12.6.2 Pre-COVID-19 Market Scenario
12.6.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.7 South Korea Biosimilar Monoclonal Antibodies Market Analysis
12.7.1 Launch Of Bevacizumab Biosimilar Onbevzi in Korea
12.7.2 Pre-COVID-19 Market Scenario
12.7.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.8 Australia Biosimilar Monoclonal Antibodies Market Analysis
12.8.1 Pre-COVID-19 Market Scenario
12.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.9 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis
12.9.1 Pre-COVID-19 Market Scenario
12.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.10 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type
12.10.1 Pre-COVID-19 Market Scenario
12.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.11 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application
12.11.1 Pre-COVID-19 Market Scenario
12.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.12 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound
12.12.1 Pre-COVID-19 Market Scenario
12.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 LAMEA Biosimilar Monoclonal Antibodies Market Analysis
13.1 LAMEA Market Outlook
13.2 LAMEA Biosimilar Monoclonal Antibodies Market by Value
13.2.1 Pre-COVID-19 Market Scenario
13.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.3 LAMEA Biosimilar Monoclonal Antibodies Market by Country
13.3.1 Pre-COVID-19 Market Scenario
13.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.4 LAMEA Biosimilar Monoclonal Antibodies Market by Type
13.4.1 Pre-COVID-19 Market Scenario
13.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.5 LAMEA Biosimilar Monoclonal Antibodies Market by Application
13.5.1 Pre-COVID-19 Market Scenario
13.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.6 LAMEA Biosimilar Monoclonal Antibodies Market by Compound
13.6.1 Pre-COVID-19 Market Scenario
13.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.7 Brazil Biosimilar Monoclonal Antibodies Market Analysis
13.7.1 Pre-COVID-19 Market Scenario
13.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.8 South Africa Biosimilar Monoclonal Antibodies Market Analysis
13.8.1 Pre-COVID-19 Market Scenario
13.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.9 Saudi Arabia Biosimilar Monoclonal Antibodies Market Analysis
13.9.1 Pre-COVID-19 Market Scenario
13.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.10 Turkey Biosimilar Monoclonal Antibodies Market Analysis
13.10.1 Pre-COVID-19 Market Scenario
13.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.11 UAE Biosimilar Monoclonal Antibodies Market Analysis
13.11.1 Pre-COVID-19 Market Scenario
13.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.12 Rest of LAMEA Biosimilar Monoclonal Antibodies Market Analysis
13.12.1 Pre-COVID-19 Market Scenario
13.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 Company Profiles
14.1 Pfizer Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Company Financial Profile
14.1.4 Company Product Benchmarking
14.1.5 Company Recent Developments
14.2 Novartis AG
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Company Financial Profile
14.2.4 Company Product Benchmarking
14.2.5 Company Recent Developments
14.3 Boehringer Ingelheim GmbH
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Company Financial Profile
14.3.4 Company Product Benchmarking
14.3.5 Company Recent Developments
14.4 Intas Pharmaceuticals Ltd.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Company Product Benchmarking
14.5 Amgen
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Company Financial Profile
14.5.4 Company Product Benchmarking
14.5.5 Company Recent Developments
14.6 Biocon
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Company Financial Profile
14.6.4 Company Product Benchmarking
14.6.5 Company Recent Developments
14.7 Celltrion Healthcare Co. Ltd
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Company Financial Profile
14.7.4 Company Product Benchmarking
14.7.5 Company Recent Developments
14.8 Dong-A Socio Holdings
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Company Financial Profile
14.8.4 Company Product Benchmarking
14.8.5 Company Recent Developments
14.9 Dr. Reddy’s Laboratories Ltd
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Company Financial Profile
14.9.4 Company Product Benchmarking
14.9.5 Company Recent Developments
14.10 3SBio
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Company Financial Profile
14.10.4 Company Product Benchmarking
14.10.5 Company Recent Developments
14.11 Allergan(AbbVie Inc.)
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Company Financial Profile
14.11.4 Company Product Benchmarking
14.11.5 Company Recent Developments
14.12 Genor BioPharma Co. Ltd.
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Company Product Benchmarking
14.12.4 Company Recent Developments
14.13 Reliance Life Sciences
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Company Product Benchmarking
14.13.4 Company Recent Developments
14.14 Torrent Pharmaceuticals
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Company Financial Profile
14.14.4 Company Product Benchmarking
14.14.5 Company Recent Developments
14.15 BIOCAD
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Company Product Benchmarking
14.15.4 Company Recent Developments
15 Conclusion and Recommendations
15.1 Conclusion Summary
15.2 Recommendations for Market Players
List of Tables
Table 1. Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 2. Global Biosimilar Monoclonal Antibodies Market Snapshot, 2022 & 2032 (US$million, CAGR %)
Table 3. List of Biosimilars Produced in E. Coli
Table 4. List of Biosimilars Produced in Mammalian Cells
Table 5. Key Differences in Approval Pathways for Biosimilars, European Union (EU) vs. United Sates (U.S.)
Table 6. US Approved Biosimilars
Table 7. Biosimilar Monoclonal Antibodies Swot Analysis
Table 8. Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 9. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 10. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 11. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 12. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 13. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 14. 50 Biopharmaceuticals Products
Table 15. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 16. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 17. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 18. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 19. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 20. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Table 21. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 22. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 23. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 24. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 25. Biosimilar Active Substance Reference Product Company
Table 26. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 27. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 28. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 29. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 30. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 31. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 32. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 33. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 34. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 35. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 36. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 37. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 38. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 39. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 40. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 41. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 42. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 43. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 44. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 45. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 46. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 47. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 48. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 49. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 50. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 51. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 52. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 53. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 54. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 55. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 56. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 57. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 58. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 59. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 60. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 61. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 62. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 63. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 64. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 65. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 66. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 67. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 68. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 69. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 70. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 71. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 72. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 73. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 74. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 75. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 76. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 77. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 78. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 79. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 80. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 81. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 82. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 83. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 84. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 85. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 86. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 87. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 88. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 89. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 90. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 91. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 92. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 93. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 94. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 95. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 96. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 97. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 98. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 99. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 100. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 101. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 102. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 103. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 104. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 105. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 106. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 107. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 108. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 109. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 110. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 111. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 112. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 113. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 114. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 115. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 116. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 117. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 118. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 119. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 120. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 121. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 122. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 123. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 124. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 125. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 126. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 127. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 128. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 129. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 130. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 131. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 132. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 133. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 134. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 135. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 136. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 137. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 138. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 139. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 140. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 141. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 142. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 143. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 144. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 145. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 146. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 147. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 148. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 149. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 150. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 151. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 152. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 153. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 154. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 155. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 156. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 157. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 158. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 159. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 160. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 161. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 162. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 163. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 164. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 165. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 166. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 167. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 168. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 169. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 170. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))

Companies Mentioned

  • 3SBio Inc.
  • AbbVie Inc. (AbbVie)
  • Amgen Inc.
  • BIOCAD
  • Biocon Limited
  • Boehringer Ingelheim
  • Celltrion Healthcare Co Ltd.
  • Dong-A Socio Holdings
  • Dr. Reddy’s Laboratories Ltd
  • Genor Biopharma Holdings Ltd.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Reliance Life Sciences
  • Torrent Pharmaceuticals Limited
  • Abdi İbrahim Pharmaceuticals
  • Adello biologics
  • AffaMed Therapeutics
  • Appobiologix
  • Aprogen Biologics Inc.
  • AYUMI Pharmaceutical
  • Baliopharm GmbH
  • Bio-Thera
  • Bioeq
  • Cadila Healthcare
  • Celltrion Healthcare Hungary Kft
  • Cinfa Biotech
  • Cipla Gulf FZ LLC
  • CuraTeQ Biologics Private Limited
  • DSM Pentapharm
  • Fuji Pharma
  • GI Innovation
  • Hisun BioRay Bio Pharmaceutical Co. Ltd.
  • Innovent Biologics
  • Intract Pharma Ltd.
  • JAMP Pharma
  • JW Pharmaceutical
  • Kamada Limited
  • Kishi Kasei Co., Ltd.
  • mAbxience
  • Mycenax
  • Nan Fung Group
  • Prestige Biopharma
  • Revance
  • Sagent Pharmaceuticals
  • Selexis
  • Synthorx
  • TR-Pharm
  • Translate Bio
  • Ultragenyx Pharmaceutical Inc.
  • Wockhardt Limited
  • YL Biologics
  • Abbreviated New Drug Application ANDA
  • Centers for Disease Control and Prevention (CDC)
  • Centers for Medicare & Medicaid Services (CMS)
  • Changchun High & New Technology Industries Group Inc. (CCHN)
  • CSIR-NCL and the DST
  • EMA
  • European Commission (EC)
  • Global Burden of Disease Study
  • Japanese Ministry of Health, Labour and Welfare
  • Japanese Ministry of Health, Labour and Welfare
  • National Center for Biotechnology Information (NCBI)
  • National Health Service (NHS)
  • National Psoriasis Foundation
  • National Health Service NHS
  • National Medical Products Administration NMPA’s
  • Organization for Economic Cooperation and Development (OECD)
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • U.S. Department of Health and Human Services
  • US FDA

Related Topics

Related Reports

Biosimilars and Follow-On Biologics Market Report 2024-2034 - Product Image

Biosimilars and Follow-On Biologics Market Report 2024-2034

  • Report
  • 391 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Global Market Report 2024 - Product Image

Biosimilar Monoclonal Antibodies Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Monoclonal Antibodies Market Report and Forecast 2024-2032 - Product Image

Monoclonal Antibodies Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030 - Product Image

Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.